Lundbeck bags a PhII Parkinson’s drug with $1.1B Prexton buyout deal

[Farooqji]

As per deal, Lundbeck is handing over $123 million and committing to about a billion dollars more in milestones — with more than half of that tied to sales goals.

Lundbeck is spending its money on a single asset being studied by Prexton : foliglurax.

Foliglurax is an investigative treatment being developed by Prexton Therapeutics for the treatment of PD.

endpts.com/lundbeck-bags-a-...

The study is expected to be completed in 2018.

[park_bear]

They are at least 4 years away from having a drug- if they succeed. Nonetheless, very interesting, and they have a cool diagram of the neural interactions here: prextontherapeutics.com/r_a...

[Farooqji in reply to park_bear]

Thanks for the additional information

[bassofspades in reply to park_bear]

this page and diagram is fascinating

[BUZZ1397]

Yay! Lundbeck made Parkensan The treatment based on the piperidine

that we can’t get in the United States boo bad FDA

[Farooqji in reply to BUZZ1397]

Are you talking about this

encrypted.google.com/patent...

or

TRADEMARK Parkinsan®

COMPOUND Budipin

FIRST REGISTRATION 1997

REGISTERED NO. OF COUNTRIES 01

[BUZZ1397 in reply to Farooqji]

Yes